{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.3","upperLimit":"42.0","value":"31.0"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"15.3","value":"6.8"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"11.8","value":"5.6"},{"groupId":"OG003","lowerLimit":"2.8","upperLimit":"33.6","value":"13.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"107"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"The confirmed response rate by RECIST v1.1 is defined as the percentage of patients with a confirmed complete response (CR) or partial response (PR) on subsequent tumor assessment at least 28 days after first response documentation. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA mutation detected in their tumor.","id":"OG000","title":"Part 2: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH.","id":"OG001","title":"Part 2: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH.","id":"OG002","title":"Part 2: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).","id":"OG003","title":"Part 2: Non-tBRCA LOH Unknown"}],"paramType":"NUMBER","populationDescription":"Safety population by HRD subgroups: Consist of all Part 2 patients who received at least one dose of rucaparib.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.","title":"Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}